{"entity":{"type":"insider","cik":"0001385116","url":"/insider/0001385116","json_url":"/insider/0001385116.json","name":"Almon Einat Brill","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":7,"first":"2008-05-14","last":"2012-05-04","span_basis":"filed_date"},"name_variants":[{"name":"Almon Einat Brill","source":"filing","n_filings":7,"first_seen":"2008-05-14","last_seen":"2012-05-04"}],"transactions":[{"id":3473094,"accession":"0001144204-12-026344","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-12-026344","line_url":"/filing/0001144204-12-026344#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (SVP, Product Development)","role_mark":"O","role_mark_label":"Officer (SVP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":166848.0,"shares_display":"166,848","price_per_share":7.13,"price_display":"7.13","price_state":"stated","total_value":1189626.24,"total_display":"1,189,626.24","total_whole":"1,189,626","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-05-02","filed_date":"2012-05-04","scope":"insider"},{"id":7281584,"accession":"0001209191-10-049624","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-10-049624","line_url":"/filing/0001209191-10-049624#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":9.29,"price_display":"9.29","price_state":"stated","total_value":139350.0,"total_display":"139,350.00","total_whole":"139,350","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-06","filed_date":"2010-10-06","scope":"insider"},{"id":7281581,"accession":"0001209191-10-049624","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-10-049624","line_url":"/filing/0001209191-10-049624#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":9.08,"price_display":"9.08","price_state":"stated","total_value":181600.0,"total_display":"181,600.00","total_whole":"181,600","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-05","filed_date":"2010-10-06","scope":"insider"},{"id":7281578,"accession":"0001209191-10-049624","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-049624","line_url":"/filing/0001209191-10-049624#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35000.0,"shares_display":"35,000","price_per_share":9.02,"price_display":"9.02","price_state":"stated","total_value":315700.0,"total_display":"315,700.00","total_whole":"315,700","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-04","filed_date":"2010-10-06","scope":"insider"},{"id":7655795,"accession":"0001209191-10-045450","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-10-045450","line_url":"/filing/0001209191-10-045450#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22500.0,"shares_display":"22,500","price_per_share":8.16,"price_display":"8.16","price_state":"stated","total_value":183600.0,"total_display":"183,600.00","total_whole":"183,600","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-09-07","filed_date":"2010-09-08","scope":"insider"},{"id":7655791,"accession":"0001209191-10-045450","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-045450","line_url":"/filing/0001209191-10-045450#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27500.0,"shares_display":"27,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":220000.0,"total_display":"220,000.00","total_whole":"220,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-09-03","filed_date":"2010-09-08","scope":"insider"},{"id":5769689,"accession":"0001209191-09-049181","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-09-049181","line_url":"/filing/0001209191-09-049181#line-5","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":38320.0,"shares_display":"38,320","price_per_share":9.43,"price_display":"9.43","price_state":"stated","total_value":361357.6,"total_display":"361,357.60","total_whole":"361,358","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-19","filed_date":"2009-10-19","scope":"insider"},{"id":5769682,"accession":"0001209191-09-049181","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-049181","line_url":"/filing/0001209191-09-049181#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23680.0,"shares_display":"23,680","price_per_share":9.39,"price_display":"9.39","price_state":"stated","total_value":222355.2,"total_display":"222,355.20","total_whole":"222,355","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-16","filed_date":"2009-10-19","scope":"insider"},{"id":5769680,"accession":"0001209191-09-049181","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-049181","line_url":"/filing/0001209191-09-049181#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28000.0,"shares_display":"28,000","price_per_share":9.39,"price_display":"9.39","price_state":"stated","total_value":262920.0,"total_display":"262,920.00","total_whole":"262,920","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-15","filed_date":"2009-10-19","scope":"insider"},{"id":5769124,"accession":"0001209191-09-036037","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-09-036037","line_url":"/filing/0001209191-09-036037#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11000.0,"shares_display":"11,000","price_per_share":4.95,"price_display":"4.95","price_state":"stated","total_value":54450.0,"total_display":"54,450.00","total_whole":"54,450","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-07-07","filed_date":"2009-07-08","scope":"insider"},{"id":5769121,"accession":"0001209191-09-036037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-036037","line_url":"/filing/0001209191-09-036037#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44000.0,"shares_display":"44,000","price_per_share":5.13,"price_display":"5.13","price_state":"stated","total_value":225720.0,"total_display":"225,720.00","total_whole":"225,720","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-07-06","filed_date":"2009-07-08","scope":"insider"},{"id":5803547,"accession":"0001209191-09-027626","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-027626","line_url":"/filing/0001209191-09-027626#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":160000.0,"total_display":"160,000.00","total_whole":"160,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-05-18","filed_date":"2009-05-19","scope":"insider"},{"id":2512185,"accession":"0001385116-08-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001385116-08-000002","line_url":"/filing/0001385116-08-000002#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385116","owner_name":"Almon Einat Brill","owner_display_name":"Almon Einat Brill","owner_url":"/insider/0001385116","role":"Officer (VP, Product Development)","role_mark":"O","role_mark_label":"Officer (VP, Product Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Product Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41427.0,"shares_display":"41,427","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":113924.25,"total_display":"113,924.25","total_whole":"113,924","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-05-12","filed_date":"2008-05-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":13,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001006281","name":"Protalix BioTherapeutics, Inc.","url":"/issuer/0001006281","role":"Officer (SVP, Product Development)","n_filings":7,"first_seen":"2008-05-14","last_seen":"2012-05-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001385116","retrieved_at":"2026-08-26T14:29:57+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}